Blinding assessment in clinical trials of traditional Chinese medicine: Exploratory principles and protocol

Measuring the success of blinding in placebo-controlled trials: should we be so quick to dismiss it?

(2021) Rebecca K Webster et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Developing Placebos for Clinical Research in Traditional Chinese Medicine: Assessing Organoleptic Properties of Three Dosage Forms (Oral Liquid, Capsule and Granule)

(2021) Mengli Xiao et al.   Frontiers in Pharmacology

Establishment of appropriate sham acupuncture and successful patient blinding

(2020) Hantong Hu et al.   Acupuncture in Medicine

The role played by traditional Chinese medicine in preventing and treating COVID-19 in China

(2020) Qingwei Li et al.   Frontiers of Medicine

TIDieR-Placebo: A guide and checklist for reporting placebo and sham controls

(2020) Jeremy Howick et al.   PLOS MEDICINE

Factors influencing the quality of clinical trials on traditional Chinese medicine—Qualitative interviews with trial auditors, clinicians and academic researchers

(2019) Xue-yan Han et al.   Complementary Therapies in Clinical Practice

Placebo design in WHO-registered trials of Chinese herbal medicine need improvements

(2019) Xuan Zhang et al.   BMC Complementary and Alternative Medicine

Effects of processing adjuvants on traditional Chinese herbs

(2018) Lin-Lin Chen et al.   JOURNAL OF FOOD AND DRUG ANALYSIS

Sample size calculations for blinding assessment

(2017) Victoria Landsman et al.   Journal of Biopharmaceutical Statistics

Unreported formal assessment of unblinding occurred in 4 of 10 randomized clinical trials, unreported loss of blinding in 1 of 10 trials

(2017) Segun Bello et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects

(2016) Fabrizio Benedetti et al.   LANCET NEUROLOGY

Observer bias in randomized clinical trials with time-to-event outcomes: systematic review of trials with both blinded and non-blinded outcome assessors

(2014) Asbjørn Hróbjartsson et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies

(2014) Asbjørn Hróbjartsson et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

The risk of unblinding was infrequently and incompletely reported in 300 randomized clinical trial publications

(2014) Segun Bello et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Systematic Review of Blinding Assessment in Randomized Controlled Trials in Schizophrenia and Affective Disorders 2000-2010

(2013) Christopher Baethge et al.   PSYCHOTHERAPY AND PSYCHOSOMATICS

Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: a new approach

(2012) Stephen Wright et al.   Trials

Non-penetrating sham needle, is it an adequate sham control in acupuncture research?

(2010) Hyangsook Lee et al.   COMPLEMENTARY THERAPIES IN MEDICINE

The reporting quality, scientific rigor, and ethics of randomized placebo-controlled trials of traditional Chinese medicine compound formulations and the differences between Chinese and non-Chinese trials

(2010) Yun-Qing Zhong et al.   CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL

CONSORT 2010 changes and testing blindness in RCTs

(2010) Kenneth F Schulz et al.   LANCET

Towards a proposal for assessment of blinding success in clinical trials: up-to-date review

(2009) Jafar Kolahi et al.   COMMUNITY DENTISTRY AND ORAL EPIDEMIOLOGY

Switching to Another SSRI or to Venlafaxine With or Without Cognitive Behavioral Therapy for Adolescents With SSRI-Resistant Depression

(2008) David Brent   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION